



Dear Geneos stakeholders and well-wishers,

As we enter 2023, I am so proud of the Geneos Therapeutics team for the patients' lives we've already transformed. In four short years, Covid disruptions of the past three years notwithstanding, Geneos has progressed from a pre-clinical stage company to having meaningful efficacy data in one of the most difficult to treat cancers, advanced Hepatocellular Carcinoma (HCC). We have done it all thanks to the incredible efforts of our employees, advisors, partners, and collaborators. Our success has been possible due to the support of our investors and their belief in our vision. Thank you.

The Geneos team has a lot to celebrate!

Our treatments led to four patients with advanced liver cancer becoming 100% tumor-free

- We reported data from our first 23 evaluable patients who were treated with their personalized therapeutic cancer vaccines in combination with the PD-1 agent pembrolizumab. The data showed patient tumors reduced by more than 30 percent in **seven of 23** (30.4 percent) patients; including three patients who had complete responses (100 percent tumor reduction). Additionally, one patient saw a 73 percent reduction in their tumor burden that led to their treating clinician to resect the remaining tumor, and this fourth patient is also now cancer-free. In comparison, studies that treated patients with PD1 agents such as pembrolizumab, nivolumab, tislelizumab, or sintilimab as single agents, reported a tumor response rate of 12 to 18 percent in the second-line advanced HCC population. Complete responses are rare in the HCC therapies available to patients – only on the order of one to two percent, which is far below the 13 percent that we have observed thus far in our ongoing clinical trial.
- We expanded the HCC trial to enroll 36 patients due to these results
- Our personalized treatments can be used to treat other cancers. The very first patient treated with our personalized therapeutic cancer vaccine--a patient with a form of brain cancer who first underwent surgery--continues to remain free of cancer for 42+ months on our therapy and 54+ months since primary surgery. We are inspired by this patient for being the first and for showing us that our treatments are feasible and have applicability to multiple cancers.

That totals five patients for Geneos, living without cancer, in our short history as a company.

We presented our clinical data at major scientific conferences

- Our data were selected for five data presentations at major conferences in 2022 - ASCO (1) and SITC (4)
- We published an article on our vaccine approach and data titled, "**Personalized cancer vaccines: more is more?**" in Vaccine Insights 2022; 1(3), 149-154 [DOI: 10.18609/vac.2022.025]
- We overhauled our website to reflect the vision and values of Geneos as a clinical-stage company.

Geneos continues to operate as a lean and highly experienced, yet nimble, team. Looking ahead, I see 2023 as a transformational year for the company. We expect to report key efficacy data from the full cohort of 36 liver cancer patients from our ongoing trial. Planning for the initiation of a Phase 2b registrational trial is underway for liver cancer, which we see as the next step toward commercialization.

I am pleased to enclose our corporate presentation for Q1-2023. More details on the GT-EPIC™ platform and our programs are at our website: www.geneostx.com

Upwards and onwards to a transformational 2023!

A handwritten signature in black ink, appearing to read "N. Sardesai".

Niranjana Y. Sardesai, Ph.D.

Founder, President & CEO

660 W Germantown Pike, Suite LL 100, Plymouth Meeting, PA 19462
Ph: 267-440-4232; Web: www.geneostx.com